.jpg)
Season 8, Post 42: “Innovation is in our DNA”
To understand the future of life sciences, travel 90km northeast of London – as your author did earlier this week – to Granta Park in Cambridge. Located on the former Abington Hall Estate, this 120-acre site is home to some 30 organisations across global pharmaceuticals, biotech and clinical research. Global businesses such as Pfizer and Thermo Fisher have buildings in Granta Park. Think of it as a collaborative hub.
Walk into the offices of Illumina, a global biotechnology leader, and you will see the strapline “innovation is in our DNA” adorn its reception. The wording is not accidental since the business develops and manufactures systems for large-scale analysis of genetic variation and biological function. Two hours with various members of the Illumina team brought to life their strategy and the imperative of pushing scientific boundaries.
“We want to give our customers more information about biology” was one of the key messages we heard from Illumina. Multiomics represents one potential solution. For those unfamiliar, think of it as an integrated approach to biology, studying multiple biological layers simultaneously. Beyond genetics, multiomics might embrace transcriptomics (which genes are active), proteomics (which proteins are produced), epigenomics (how genes are regulated) and so on.
Put the pieces together and you have an operating system for biological data where “the sum has to be greater than the parts”, according to Illumina. Some of its products already on the market have the potential to analyse over 9,000 proteins from just one prep sample. Over time, Illumina believes that expansion beyond genomics into areas such as proteomics can “accelerate innovation, expand access and reduce cost.” Oncology represents one promising application; neurological disease another.
Multiomics is still a nascent discipline. Your author was left in no doubt that it can generate more medical data. The investment thesis, however, ultimately depends on whether more data becomes better medicine. “You won’t know if you don’t try”, as one presenter said to us. Watch this space. Our first theme piece of 2027 will discuss the topic in more detail.
19 November 2026
The above is provided for information purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Any forward looking statements are based on assumptions that may change. The views expressed are solely those of the author at the time of writing. The author of this piece has no personal direct investment in the business. This article should not be relied upon for investment decisions. Past performance does not predict future returns, the value of investments and income from them can fall as well as rise.
Disclaimers
The document is provided for information purposes only and does not constitute investment advice or any recommendation to buy, or sell or otherwise transact in any investments. The document is not intended to be construed as investment research. The contents of this document are based upon sources of information which Heptagon Capital LLP believes to be reliable. However, except to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to the accuracy or completeness of this document or its contents and, Heptagon Capital LLP, its affiliate companies and its members, officers, employees, agents and advisors do not accept any liability or responsibility in respect of the information or any views expressed herein. Opinions expressed whether in general or in both on the performance of individual investments and in a wider economic context represent the views of the contributor at the time of preparation. Where this document provides forward-looking statements which are based on relevant reports, current opinions, expectations and projections, actual results could differ materially from those anticipated in such statements. All opinions and estimates included in the document are subject to change without notice and Heptagon Capital LLP is under no obligation to update or revise information contained in the document. Furthermore, Heptagon Capital LLP disclaims any liability for any loss, damage, costs or expenses (including direct, indirect, special and consequential) howsoever arising which any person may suffer or incur as a result of viewing or utilising any information included in this document.
The document is protected by copyright. The use of any trademarks and logos displayed in the document without Heptagon Capital LLP’s prior written consent is strictly prohibited. Information in the document must not be published or redistributed without Heptagon Capital LLP’s prior written consent.
Heptagon Capital LLP, 63 Brook
Street, Mayfair, London W1K 4HS
tel +44 20 7070
1800
email [email protected]
Partnership No: OC307355 Registered in England and Wales Authorised & Regulated by the Financial Conduct Authority
Heptagon Capital Limited is licenced to conduct investment services by the Malta Financial Services Authority.
Receive the updates
Sign up to our monthly email newsletter for the latest fund updates, webcasts and insights.